Guidewire Software Inc. Common Stock vs 22nd Century Group Inc — how do they compare? Guidewire Software Inc. Common Stock trades at $165.76 (market cap $13.59B), while 22nd Century Group Inc trades at $0.65 (market cap $475.95K). The key difference: Guidewire Software Inc. Common Stock is far larger — about 28553.4× 22nd Century Group Inc's market cap, and Guidewire Software Inc. Common Stock is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Guidewire Software Inc. Common Stock for 0 Days and 22nd Century Group Inc for 33 Days on average.
| GWRE | XXII | |
|---|---|---|
Market Cap | $13.59B | $475.95K |
Volume | 838,274 | 78,911 |
Sector | Technology | Consumer Staples |
52-Week High | $254.23 | $483.00 |
52-Week Low | $102.69 | $0.65 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $13.55B | -$3.83M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $0.67, down 7.98% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.06 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives in France and Europe.
Despite analyst optimism (75% buy ratings with $1,240 price target), fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces significant execution risk in commercializing reduced-nicotine tobacco products while navigating regulatory timelines.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Guidewire Software Inc. develops InsuranceSuite Cloud, a software platform used by property and casualty insurers for policy administration, billing, and claims processing.
Read more on GWRE →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →